Patents by Inventor Snorri S. Thorgeirsson
Snorri S. Thorgeirsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9222086Abstract: The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.Type: GrantFiled: September 23, 2010Date of Patent: December 29, 2015Assignees: PROTIVA BIOTHERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Adam Judge, Yun-Han Lee, Ian MacLachlan, Snorri S. Thorgeirsson
-
Publication number: 20130178511Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: ApplicationFiled: July 17, 2012Publication date: July 11, 2013Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20130065939Abstract: The present invention provides therapeutic nucleic acids such as interfering RNA (e.g., siRNA) that target the expression of genes associated with tumorigenesis and/or cell transformation, lipid particles (e.g., nucleic acid-lipid particles) comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles, e.g., for the treatment of a cell proliferative disorder such as cancer.Type: ApplicationFiled: September 23, 2010Publication date: March 14, 2013Applicants: Protiva Biotherapeutics, Inc., Department of Health and Human ServicesInventors: Adam Judge, Yun-Han Lee, Ian MacLachlan, Snorri S. Thorgeirsson
-
Patent number: 8227443Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: GrantFiled: October 13, 2010Date of Patent: July 24, 2012Assignees: Protiva Biotherapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20110178155Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: ApplicationFiled: October 13, 2010Publication date: July 21, 2011Applicants: Protiva Biotherapeutics, Inc., The USA, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20100129791Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-?1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.Type: ApplicationFiled: December 14, 2007Publication date: May 27, 2010Applicant: The Government of the United State, as represented by the Secretary, Dept. of Health & Human ServiceInventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
-
Publication number: 20090239220Abstract: A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.Type: ApplicationFiled: September 26, 2008Publication date: September 24, 2009Inventors: BAO-ZHU YUAN, SNORRI S. THORGEIRSSON, NICOLAS POPESCU
-
Patent number: 7534565Abstract: A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.Type: GrantFiled: November 22, 2004Date of Patent: May 19, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Bao-Zhu Yuan, Snorri S. Thorgeirsson, Nicholas Popescu
-
Patent number: 7342099Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-?1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.Type: GrantFiled: February 5, 2004Date of Patent: March 11, 2008Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
-
Patent number: 6897018Abstract: A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented.Type: GrantFiled: August 23, 2000Date of Patent: May 24, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Bao-Zhu Yuan, Snorri S. Thorgeirsson, Nicholas Popescu
-
Publication number: 20040139485Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-&bgr;1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.Type: ApplicationFiled: February 5, 2004Publication date: July 15, 2004Applicant: The Government of the U.S. A, as presented by the Secretary, Department of Health and Human ServicesInventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
-
Patent number: 6727079Abstract: Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-&bgr;1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided.Type: GrantFiled: August 11, 2000Date of Patent: April 27, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Snorri S. Thorgeirsson, Joseph T. Woitach, Minghuang Zhang
-
Patent number: 5081584Abstract: A computer-implemented method for designing at least one anti-peptide sequence having affinity for target peptide or a fragment thereof suitable for synthesizing peptides and micromolecules, assaying for a target peptides, purifying target peptides, and/or preventing proteolyis of a polypeptide includes identification of the members of the amino acid sequence of the target peptide and their anti-sense or hydropathically complementary amino acids and determining the moving average hydropathy for the target and anti-sense members. The resulting lowest hydropathy identifies the anti-sense amino acid sequence for the target peptide. The members of the target peptide amino acid sequence are obtained along with their member-specific hydropathic values with the hydropathic values summed as a moving average. Anti-sense or complementary amino acid members are identified from the moving average information to generate an array of anti-sense amino acid sequences.Type: GrantFiled: March 13, 1989Date of Patent: January 14, 1992Assignee: United States of AmericaInventors: James G. Omichinski, Giorgio Fassina, Arthur D. Olson, Snorri S. Thorgeirsson